Pacira (PCRX) BioSciences announced an upcoming podium presentation of findings from its Phase 1 study of PCRX-201, a locally administered gene therapy candidate for osteoarthritis of the knee. The data will be presented at the 28th Annual Meeting of the American Society of Gene and Cell Therapy in New Orleans on May 15. The presentation will highlight how preexisting and treatment-induced neutralizing antibodies impact the therapy’s efficacy, safety, and redosing potential.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue